Clinical Trials
980 trialsNCT04070209 2026-05-27
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Active not recruiting
NCT03570827 2026-05-26
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
Mayo Clinic
Phase 2 Completed
NCT03934840 2026-05-26
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT05496959 2026-05-26
LUNAR
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04007770 2026-05-22
Acupuncture Pilot Study for Cancer-related Cognitive Function
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT01885949 2026-05-20
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT04879940 2026-05-20
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03606837 2026-05-19
PROSTATEP
University Hospital, Bordeaux
Phase 2 Completed
NCT04346225 2026-05-19
Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer
University of California, San Francisco
Phase 2 Recruiting
NCT03933670 2026-05-18
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
University of California, San Francisco
Phase 2 Recruiting
NCT05751434 2026-05-18
A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT07285044 2026-05-18
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase 2 Recruiting
NCT07592910 2026-05-18
MOMENT
Prostate Cancer Clinical Trials Consortium
Phase 2 Not yet recruiting
NCT07593079 2026-05-18
Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT00183937 2026-05-15
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
University of Southern California
Phase 2 Terminated
NCT04019964 2026-05-15
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT04565496 2026-05-15
PEM-PRO
IRCCS San Raffaele
Phase 2 Withdrawn
NCT04716725 2026-05-15
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT04947254 2026-05-15
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05730712 2026-05-15
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT02312557 2026-05-14
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT03604757 2026-05-14
UROPET
University Hospital, Bordeaux
Phase 2 Completed
NCT04030559 2026-05-14
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
University of California, Davis
Phase 2 Terminated
NCT05168618 2026-05-14
AtezoCab
University of Utah
Phase 2 Recruiting
NCT05169970 2026-05-13
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07455903 2026-05-13
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Baptist Health South Florida
Phase 2 Recruiting
NCT04731844 2026-05-12
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
University of Rochester
Phase 2 Completed
NCT04262154 2026-05-11
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05689021 2026-05-11
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
Mayo Clinic
Phase 2 Active not recruiting
NCT06111781 2026-05-11
The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
Yale University
Phase 2 Recruiting
NCT07578519 2026-05-11
Radiation Treatment of the Prostate That is Specially Adjusted for Each Person
AHS Cancer Control Alberta
Phase 2 Not yet recruiting
NCT03637543 2026-05-08
Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT05826509 2026-05-08
SUGAR
Institut Claudius Regaud
Phase 2 Active not recruiting
NCT06632977 2026-05-08
PREDICT
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT03824652 2026-05-07
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT06212583 2026-05-06
KNIGHTS
University of Maryland, Baltimore
Phase 2 Active not recruiting
NCT07568444 2026-05-06
Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)
University of Southern California
Phase 2 Completed
NCT07568756 2026-05-06
Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation
University of California, Irvine
Phase 2 Not yet recruiting
NCT03899987 2026-05-05
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
Roswell Park Cancer Institute
Phase 2 Active not recruiting
NCT05873192 2026-05-05
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07354919 2026-05-05
AxeCan
HealthPartners Institute
Phase 2 Recruiting
NCT07568236 2026-05-05
A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)
Chinese University of Hong Kong
Phase 2 Not yet recruiting
NCT05053152 2026-05-04
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NRG Oncology
Phase 2 Active not recruiting
NCT07223385 2026-05-04
High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)
Cedars-Sinai Medical Center
Phase 2 Not yet recruiting
NCT07226713 2026-05-04
POSTPONE
Medical College of Wisconsin
Phase 2 Not yet recruiting
NCT04631744 2026-05-01
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Weill Medical College of Cornell University
Phase 2 Terminated
NCT07562438 2026-05-01
Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
First Affiliated Hospital of Fujian Medical University
Phase 2 Recruiting
NCT07451795 2026-04-30
SHARP
Fudan University
Phase 2 Recruiting
NCT05133440 2026-04-28
A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT06630325 2026-04-28
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated